ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca is advancing small-molecule drugs for cancer and heart disease with an acquisition and a licensing deal, respectively. The British drug firm has agreed to acquire KuDOS Pharmaceuticals, also of the U.K., for $210 million in cash. AstraZeneca is particularly interested in a KuDOS drug, KU 59436, that stops tumor cells from repairing damaged DNA by inhibiting an enzyme involved in the process. AstraZeneca says KuDOS will become a hub for DNA repair discovery within its cancer and infection research area. Meanwhile, AstraZeneca has signed a deal to develop AtheroGenics' anti-inflammatory cardiovascular drug candidate, AGI-1067, now in Phase III trials. AtheroGenics will receive an up-front fee of $50 million and up to $300 million in development and regulatory milestones. It could reap further sales-related milestones of up to $650 million, for total payments of $1 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter